Header Image

News

News

Filter Releases
 
News
Date Title and Summary View
Nov 16, 2017
RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company's clinical programs at the 29th Annual Piper Jaffray Healthcare Conference in New York on November 28, 2017 at 3...
Nov 7, 2017
BCX7353 Phase 3 program agreed with FDA and EMA U.S. Orphan Drug designation for BCX7353 received from FDA RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today financial results for the third quarter ended September 30, 2017. "Now that we have completed our end of Phas...
Nov 1, 2017
RESEARCH TRIANGLE PARK, N.C., Nov. 01, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company's clinical programs at the Jefferies 2017 London Healthcare Conference on November 15, 2017 at 4:40 p.m. Greenwi...
Oct 27, 2017
RESEARCH TRIANGLE PARK, N.C., Oct. 27, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that results from its successful Phase 2 APeX-1 clinical trial in hereditary angioedema (HAE) will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2017 Annual Scientific Meeting taking place in ...
Oct 24, 2017
RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that its third quarter 2017 financial results will be reported on Tuesday, November 7, 2017. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss financial results and to provide an up...
Oct 4, 2017
RESEARCH TRIANGLE PARK, N.C., Oct. 04, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that interim results from a clinical trial of a single IV dose of RAPIVAB® (peramivir injection) for the treatment of pediatric influenza and results from preclinical studies of galidesivir (BCX4430) in Rhesus macaques...
Sep 21, 2017
RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) a biotechnology company focused on the development and commercialization of treatments for rare and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application for...
Sep 15, 2017
RESEARCH TRIANGLE PARK, N.C., Sept. 15, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) announced today the completion of an underwritten public offering of 17,864,078 shares of its common stock, including 2,330,097 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares.  The g...
Sep 12, 2017
RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) announced today the pricing of an underwritten public offering of 15,533,981 shares of its common stock, offered at a price to the public of $5.15 per share.  The gross proceeds from this offering to BioCryst are expected to be $80 millio...
Sep 11, 2017
RESEARCH TRIANGLE PARK, N.C., Sept. 11, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) a biotechnology company focused on the development and commercialization of treatments for rare and infectious diseases, announced today that it is offering to sell $80 million of its common stock in an underwritten public offering. As pa...
Sep 5, 2017
73% Reduction in Overall Attack Frequency at 125mg Dose (p...
Sep 4, 2017
RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company will host a conference call on Tuesday, September 5, 2017, at 9:00 a.m. Eastern Time to provide an update on the Company's activities and progress. To participate in the conference call, pl...
Aug 23, 2017
RESEARCH TRIANGLE PARK, N.C., Aug. 23, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company's clinical programs at the following investor conferences: The Robert W. Baird's 2017 Global Healthcare Con...
Aug 7, 2017
RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today financial results for the second quarter ended June 30, 2017. "We are excited by the positive results previously reported in Parts 1 and 2 of the APeX-1 clinical trial that indicate we have an active oral drug, and loo...
Aug 2, 2017
RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today the dosing of the first subject into ZENITH-1, a clinical trial studying up to three dosage strengths of a liquid formulation of BCX7353 given as a single oral dose for the acute treatment of angioedema attacks in patients ...
Page:
...
Next Last